Day: May 20, 2020

   Paris, le 20 mai 2020 – Sodexo, leader mondial des Services de Qualité de Vie, annonce le lancement mondial de « Rise with Sodexo », programme destiné à ses clients pour répondre  aux défis sanitaire, opérationnel et de confiance posés par l’installation dans le temps de la pandémie de COVID-19 dans le monde.Alors que de nombreux pays sortent progressivement du confinement, les salariés veulent se sentir en sécurité sur leur lieu de travail et voir leurs attentes prises en compte lorsqu’ils télétravaillent. Les consommateurs doivent être certains de pouvoir compter sur les entreprises auxquelles ils accordent leur confiance parce qu’elles adoptent les normes de santé et de sécurité les plus élevées.Dans ce contexte, convaincu que la valeur de nos expertises et de nos services, et de nos engagements en responsabilité d’entreprise...

NEWMARKET, Ontario, May 20, 2020 (GLOBE NEWSWIRE) — AirBoss of America Corp. (TSX:BOS) today announced that AirBoss Defense Group (“ADG”) is donating highly specialized life-saving personal protective equipment to Toronto Paramedic Services. Five negative-pressure individual patient isolation and transportation systems, known as ISO-PODs, will be added to the Service’s resources.“We’re grateful to AirBoss for this donation during the ongoing pandemic,” said Gord McEachen, Chief of Toronto Paramedic Services.  “If required, these ISO-POD units can be utilized to transport patients infected with any highly contagious disease, including COVID-19, in total isolation while ensuring the safety of our paramedics and other frontline healthcare workers.”ADG designed the ISO-POD to protect first-responders, while simultaneously...

CAMBRIDGE, Mass., May 20, 2020 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced today it has entered into a clinical trial collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, through a subsidiary, to evaluate the safety and efficacy of combining Surface’s SRF617, an investigational antibody therapy targeting CD39, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. This combination will be studied as a component of the first-in-human Phase 1/1b study of SRF617 and will be evaluated in patients with solid tumors, with a focus on patients with gastric cancer and those who have developed resistance to checkpoint inhibition...

SALT LAKE CITY, May 20, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) approved the BRACAnalysis CDx®  test for use as a companion diagnostic by healthcare professionals to identify men with metastatic castration-resistant prostate cancer (mCRPC) who are eligible for treatment with Lynparza® (olaparib). Lynparza is approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Lynparza is a novel PARP inhibitor jointly developed and commercialized by AstraZeneca (LSE/STO/NYSE:...

ALACHUA, Fla., May 20, 2020 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president will present at the Jefferies Virtual Healthcare Conference. The presentation is scheduled for Wednesday, June 3, 2020 at 2:00 p.m. ET.The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.About AxogenAxogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair....

CAMBRIDGE, Mass. and BEIJING, China, May 20, 2020 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Company will present at the Bernstein 36th Annual Strategic Decisions Conference on Wednesday, May 27, 2020 at 8:00 a.m. ET.A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available following the event for 90 days.About BeiGeneBeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access...

F-Secure Corporation, Stock Exchange Release, 20 May 2020, at 14.00 EESTF-Secure Corporation – Managers’ Transactions – Risto SiilasmaaF-Secure Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Siilasmaa, RistoPosition: Member of the Board/Deputy memberIssuer: F-Secure OyjLEI: 743700ATXLT0MFCHXT16Notification type: INITIAL NOTIFICATIONReference number: 743700ATXLT0MFCHXT16_20200514130205_3____________________________________________Transaction date: 2020-05-19Venue not applicableInstrument type: SHAREISIN: FI0009801310Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATIONTransaction details(1): Volume: 11,510 Unit price: 0 EURAggregated transactions(1): Volume: 11,510 Volume weighted average price: 0 EURContact...

F-Secure Oyj, Pörssitiedote, 20.5.2020 klo 14.00F-Secure Oyj – Johdon liiketoimet – Risto SiilasmaaF-Secure Oyj – Johdon liiketoimet____________________________________________IlmoitusvelvollinenNimi: Siilasmaa, RistoAsema: Hallituksen jäsen/varajäsenLiikkeeseenlaskija: F-Secure OyjLEI: 743700ATXLT0MFCHXT16Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 743700ATXLT0MFCHXT16_20200514130205_3____________________________________________Liiketoimen päivämäärä: 2020-05-19Kauppapaikka ei sovelluInstrumenttityyppi: OSAKEISIN: FI0009801310Liiketoimen luonne: OSAKEPALKKION VASTAANOTTAMINENLiiketoimien yksityiskohtaiset tiedot(1): Volyymi: 11 510 Yksikköhinta: 0 EURLiiketoimien yhdistetyt tiedot(1): Volyymi: 11 510 Keskihinta: 0 EURLisätietoja:Tiina Sarhimaa, Lakiasiainjohtaja, F-Secure Oyj+358 50 561 0080investor-relation...

YAVNE, Israel, May 20, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced financial results for the first quarter ended March 31, 2020 and provided business and financial updates related to the COVID-19 pandemic. First Quarter Business and Financial Highlights:Total revenues for the first quarter of 2020 were $4.4 million Operating loss for the first quarter of 2020 was $2.2 million, representing a 38% decrease compared to prior-year period Operating cash flow was $2.1 million, and as of March 31, 2020, the company had $27.3 million in cash and short-term investments Subsequent to the end of the quarter, the Company resumed patient screening and randomization in...

F-Secure Corporation, Stock Exchange Release, 20 May 2020, at 14.00 EESTF-Secure Corporation – Managers’ Transactions – Pertti ErviF-Secure Oyj – Managers’ Transactions____________________________________________Person subject to the notification requirementName: Ervi, PerttiPosition: Member of the Board/Deputy memberIssuer: F-Secure OyjLEI: 743700ATXLT0MFCHXT16Notification type: INITIAL NOTIFICATIONReference number: 743700ATXLT0MFCHXT16_20200514130854_3____________________________________________Transaction date: 2020-05-19Venue not applicableInstrument type: SHAREISIN: FI0009801310Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATIONTransaction details(1): Volume: 6,906 Unit price: 0 EURAggregated transactions(1): Volume: 6,906 Volume weighted average price: 0 EURContact information:Tiina...